WiDr (ATCC® CCL-218)

Organism: Homo sapiens, human  /  Tissue: colon  /  Disease: colorectal adenocarcinoma

Organism Homo sapiens, human
Tissue
colon
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease colorectal adenocarcinoma
Gender female
Applications
transfection host
Images
Derivation
Although deposited with the ATCC as a colon adenocarcinoma line established from a 78 year old female, DNA fingerprinting has shown this line to be a derivative of HT-29 (ATCC HTB-38).
­
Clinical Data
Although deposited with the ATCC as a colon adenocarcinoma line established from a 78 year old female, DNA fingerprinting has shown this line to be a derivative of HT-29 (ATCC HTB-38).
female
Antigen Expression
HLA A24, A32, B15, B18
Receptor Expression
epidermal growth factor (EGF)
Genes Expressed
­
carcinoembryonic antigen (CEA) 118 ng/10 exp6 cells/10 days; Colon Specific Antigen (CSAp); transforming growth factor beta; keratin,HLA A24, A32, B15, B18. The cells are positive for keratin by immunoperoxidase staining. The cells expressed p53 antigen (the p53 produced has a G -> A mutation resulting in Arg -> His at position 273).
Tumorigenic Yes
Effects
Yes, in nude mice
Comments
Although deposited with the ATCC as a colon adenocarcinoma line established from a 78 year old female, DNA fingerprinting has shown this line to be a derivative of HT-29 (ATCC HTB-38).
The cells are negative for Colon Antigen 3 expression.
The cells are positive for keratin by immunoperoxidase staining.
The cells expressed p53 antigen (the p53 produced has a G -> A mutation resulting in Arg -> His at position 273).
Growth of WiDr cells is inhibited by tumor necrosis factor alpha (TNF alpha).
Inhibitors of dihydrofolate reductase are highly cytotoxic to WiDr cells.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing

Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.

Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:12 is recommended
Medium Renewal: Twice per week
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 11,12
D16S539: 11,12
D5S818: 11,12
D7S820: 10
THO1: 6,9
TPOX: 8,9
vWA: 17,19
Isoenzymes
ES-D, 1
G6PD, B
PEP-D, 1
PGD, A
PGM1, 1-2
PGM3, 1-2
Name of Depositor P Noguchi
References

Noguchi P, et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-408, 1979. PubMed: 90012

Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111

Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

Smith SG, et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. 53: 5697-5706, 1993. PubMed: 8242626

Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

Petricciani JC, et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res. 34: 105-108, 1974. PubMed: 4203458

Tsuboi KK, Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res. 38: 3745-3750, 1978. PubMed: 698934

Noguchi PD, et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. PubMed: 203036

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963

Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells

Basic Documentation
Other Documentation
References

Noguchi P, et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-408, 1979. PubMed: 90012

Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111

Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

Smith SG, et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. 53: 5697-5706, 1993. PubMed: 8242626

Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

Petricciani JC, et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res. 34: 105-108, 1974. PubMed: 4203458

Tsuboi KK, Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res. 38: 3745-3750, 1978. PubMed: 698934

Noguchi PD, et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. PubMed: 203036

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963

Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells